PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Control himber

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Co	mplete if Known	7
Application Number	09/752.619	
Filing Date	December 29, 2000-	
First Named Inventor	Jesse Salb	
Art Unit	1616	J' 82 SY
Examiner Name	Dameron Jones	76 VO
Attorney Docket Number	04646.P003D	1600
	_	2900
T DOCUMENTS		7 %
Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	Closs/

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code ² (If known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
157		US- 4,474,747	10 - 02 - 1984	Dimo et al.	
	(alternative dependent	US- 4,887,604 US- 5,043,152	12 - 19 - 1989 08 - 27 - 1991	Shefer et al. Schaefer et al.	and the state of t
		US- 5,609,851	03 - 11 - 1997		
	. I produce a montage o	US- 5,817,289 US- 6,071,491	10 - 06 - 1998 06 - 06 - 2000	Klaveness et al.	***************************************
I Y	`	us- 5,650,135	07-22-1997	Epstein et al. Contag et al.	
10	<u>/</u>]			Pawlicki et al.	
		us-	;		
	•••••	US-			
		us-	••••••		
tananda sada sasa isan arabas.	****	US-			
		US-			
	••••	US-			
	•••••	US-			
		US-	به والوقوب و مستون بليد من أن يون و الما الواد الما الواد الما الواد الما الما الما الما الما الما الما ال	***************************************	······································
		us-			

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials		Foreign Patent Document Coursy Code 3 -Number 4 - Kind Code 5 (# Isrown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
a repare de material de se	anner, spilatery.					

Examiner Signature Considered 5/29/5

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspio.gov.org/ or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 5 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

===						
Nov 1 5	DE JOH				PTO/SB/08B (10-0	
CMA	DBW.	Act of 1	995, no persons are req		ruse through 10/31/2002. OM8 0651-003 ffice: U.S. DEPARTMENT OF COMMERC of Information unless it contains a valid ON	
CM A	beat	Act of 1	995, no persons are requ	Con	ruse through 10/31/2002. OMB 0651-003 ffice: U.S. DEPARTMENT OF COMMERC of Information unless it contains a valid ON mpl te if Known	
Substitute for	or form 14498/PTO			Co. Application Number	ruse through 10/31/2002. OMB 0651-003 ffice: U.S. DEPARTMENT OF COMMERC of Information unless it contains a valid ON mpl te if Known 09/752,619	
Substitute for	or form 1449B/PTO	DIS	CLOSURE	Co. Application Number Filing Date	ruse through 10/31/2002. OMB 0651-003 ffice: U.S. DEPARTMENT OF COMMERC If Information unless it contains a valid OM mpl te if Known 09/752,619 December 29, 2000	
Substitute for	or form 1449B/PTO	DIS		Con Application Number Filing Date First Named Inventor	ruse through 10/31/2002. OMB 0651-003 ffice: U.S. DEPARTMENT OF COMMERC finformation unless it contains a valid ON mpl te if Known 09/752,619 December 29, 2000 Jesse Salb	1000 CO
Substitute for NFOF	or form 1449B/PTO	DIS(Y AF	CLOSURE	Co. Application Number Filing Date	ruse through 10/31/2002. OMB 0651-003 ffice: U.S. DEPARTMENT OF COMMERC If Information unless it contains a valid OM mpl te if Known 09/752,619 December 29, 2000	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.	1
PO		ANDERSON et al., "What does positron emission tomography offer oncology?". Eur. J. Cancer 36:2028-2035 (2000).	
1/		BENDER et al., "Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer", <i>Hybridoma</i> 18: 87-91 (1999).	
		BROCK et al., "Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas". <i>Br. J. Cancer</i> 82:608-615 (2000).	
		CONTI et al., "PET and [18F]-FDG in oncology: a clinical update", Nuc. Med. Biol. 23:717-735 (1996).	
		DEHDASHTI et al., "Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy", Eur. J. Nucl. Med. 26: 51-56 (1999).	Ì
		FINDLAY et al., "Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil", J. Clin. Oncol. 14: 700-708 (1996).	
		FISCHMAN, "Positron Emission Tomography in the Clinical Evaluation of Metastatic Cancer", J. Clin. Oncol. 14: 691-696 (1996).	
		FISCHMAN, "The role of positron emission tomography in pharmacokinetic analysis", Drug Metab. Rev. 29: 923-956 (1997).	
		FOWLER et al., "PET and drug research and development". J. Nucl. Med. 40:1154-1163 (1999).	
	:	GERAN et al., " Protocols for screening chemical agents and natural products against animal tumors and other biological systems", <i>Cancer Chemother. Rep.</i> 3: 51-61 (1972).	
5X		GREEN et al., "Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose", <i>J. Nucl. Med.</i> 39: 729-734 (1998).	

Examiner Signature	Down)	Date Considered 5/2	9/63

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

/	6	TF	E	Cy
温	NOV	1	5 2002	پويند د

Approved for use through 10/31/2002 OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Control number

Traduction form 1449B/PTO

Substitute for form 1449B/PTO

Substitute for form 1449B/PTO

Application Number 09/752.619

Filling Date December 29, 2000

First Named Inventor Jesse Salb

Tones

Tones

04646.P003D

Examiner Cite Initials No.						
Dr		HENDRIKSE et al., "Visualization of multidrug resistance in vivo". <i>Eur. J. Nucl. Med.</i> 26:283-293 (1999).				
	1	HIETALA, "Ligand-receptor interactions as studied by PET: implications for drug development", Ann. Med. 31: 438-443 (1999).				
		HOH et al., "PET in oncology: will it replace the other modalities?", Semin. Nuc. Med. 27:94-106 (1997).				
		HOEY & SMITH, in Sovak ed., "Handbook of Experimental Pharmacology: Radiocontrast Agents", 73: 22-125, Springer-Verlag, NEW YORK (1984).				
		JERUSALEM et al., "Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", <i>Blood</i> 94: 429-433 (1999).				
		KNUUTI et al. "PET as a cardiovascular and metabolic research tool", Ann. Med. 31: 450-456 (1999).				
1		PRICE & JONES "Can Positron Emission Tomography (PET) be Used to Detect Subclinical Response to Cancer Therapy?", Eur J Cancer 31A: 1924-1927 (1995).	••••			
		ROMER et al., "Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose", <i>Blood</i> 91; 4464-4471 (1998).				
		SCHELLING et al., "Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer". J. Clin. Oncol. 18:1689-1695 (2000).	••••			
V		SCHULTE et al., "Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET". J Nucl. Med. 40: 1637-1643 (1999)	******			
\mathcal{Y}		SMITH et al., "Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy", J. Clin. Oncol. 18:1676-1688 (2000).	••••			

Evaninas	47			Data	1	7
Examiner Signature	1	lumin	_	Date Considered	Shi	100

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

NOV 1 5 2002

NOV 1 5 2002

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet of

Col	mplete if Kn wn		KY
Application Number	09/752,619	. 1/	
Filing Date	December 29, 2007		7, \ //.
First Named Inventor	Jesse Salb	CALL	
Group Art Unit	1616		
Examiner Name	Dameron Jones	_	
Attorney Docket Number	04646.P003D		Y0002
TENT LITERATURE DO	DCUMENTS		78%
LETTERS), title of the article (v symposium, catalog, etc.), date	T ²	1	

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), oublisher city and/or country where published	1
60	SOVAK et al. "Contrast media: a journey almost sentimental". Invest Radiol. 29: Suppl 1:S4-14 (1994).	
}	VALLBURG et al. "Drug development, radiolabelled drugs and PET", Ann. Med. 31: 432-437 (1999).	-
	WAHL et al., "Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation", <i>J. Clin. Oncol.</i> 11: 2101-2111 (1993).	
	WEBER et al., "Reproducibility of metabolic measurements in malignant tumors using FDG PET", J. Nucl. Med. 11:1771-1777 (1999).	er -ens
	YOSHIOKA et al., "Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice", J Nucl. Med 38: 714-717 (1997).	
	ZHANG et al., "Bioluminescence for biological sensing in living mammals". <i>Adv. Exp. Med. Biol.</i> 471:775-784 (1999).	
\mathbb{V}	PCT International Search Report for PCT Appln No. PCT/US01/08485, mailed 10-24-01 (9 pages).	
	PCT International Search Report for PCT Appln No. PCT/US01/08663, mailed 10-24-01 (9 pages).	
		ļ

Examiner Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through ditation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substit		Form 1449A/P nany sheets as nece			Attorney Docket No.: 04646.P003D		Application N 09/752,619	umber:		
				R 92.0	First Named Inventor: Jesse Salb					
Page	1 of _	2	PADENA PADENA	RIT OFFICE	Filing Date: 12/29/2000		_			
				U.S. PATE	NT DOCUMENTS					
Exam. Initial*	Cite No. ¹	Number	Kind Code (If known)	Na	me of Patentee or Applicant of Cited Document	0	Date of Publication of Cited Document MM-DD-YYYY	Pages, Colu Lines, WI Relevant Pa or Relevant I Appea	iere ssages Figures	(1°
TO I		4,139,605	B1		Felder et al.	()2-13-1979	прреш		લ
1/1		4,160,015	B1		Wiegert		7-03-1979			ſ
		3,702,866	B1		Salvesen et al.	1	1-14-1972	<u> </u>		\perp
		4,341,756	B1		Sovak et al.		7-27-1982	유		2
		4,352,788	B1		Felder et al.		0-05-1982	CH CH	8	丌
\perp		4,348,377	B1		Felder et al.		9-07-1982	- 3	-=	Œ.
		4,439,613	B1		Sovak et al.		3-27-1984	NTER	**	đr
_		4,766,110	B1		Ryan et al.		8-23-1988	=======================================	~~~	
		4,021,481	B1		Almen et al.		5-03-1977	1600/2900	2002	*
ΔM		2,840,602	B1		Larsen		6-24-1958	(
17		5,525,327	B1		Baker et al.	0	6-11-1996	8		Ψ
14/		4,406,878	B1		DeBoer	0	9-27-1983			y
						+				

Exam.	Cite	Fe	oreign Patent	Document		EIGN PATENT DOCUMENTS Name of Patentee or Applicant	Date of	Pages, Columns,	Т т6
Initial*	No. ¹	Office ³	Number ⁴	Kind C (If kno		of Cited Document	Publication of Cited Document MM-DD-YYYY	Lines, Where Relevant Passages or Relevant Figures Appear	1
4	-	WIPO	WO 01,	/67958	A2	Veritas Pharmaceuticals, Inc.	09-20-2001		
							 		
					 				

Examiner
Signature

Date Considered

5/29/6-3

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard S.3). 'For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Substitute (use	for For	rm 1449A/PTO (y sheets as necessary) \ 0, \(\sigma\)	Attorney Docket No.: 04646.P003D	Application Num 09/752,619	ıber:
			HOW 1 8 2002 6	First Named Inventor: Jesse Salb		
Page 2	of2	2	RADBARHER TRADBARHER	Filing Date: 12/29/2000		
		OT	HER ART - NO PATE	NT LITERATURE DOCUME	NTS	
Examiner Initials*	Cite No ¹	Include name of the item (book, magazine, journal, s	AL LETTERS), title of the article (w serial, symposium, catalog, etc.), do ner, city and/or country where pub	ate nage(s) volumo	Translation ²
N)	PCT Internation	onal Search Report for 3 9 pages).	PCT Int'l Appln No. US01/086	12, mailed 16	TECH
	/	I Movel Glucosi	et al. "Synthesis of Rac e Analogs," <u>Nuclear M</u> ent No. XP-001037809.	lioiodinated 1-Deoxy-Nojirimyo edicine and Biology, Vol. 26, No	cin Derivatives: D. 7, p. 833-839	NOV 2 2 CENTER
		Derivative wit	n interaction to Hexoki	opment of a Novel Radioiodina inase," <u>Iournal of Labelled Com</u> p. 317-328 (1992), Document N	mounds and	NOV 2 2 2002 TECH CENTER (600/2900
W		Linaging, Jour	" ¹²³ I-Iodobenzoylgluco mal of Labelled Compo 3), Document No. XP-0	osamines: Glucose Analogues in ounds and Radiopharmaceutica 108002378.	for Heart <u>ls</u> , Vol. 33, No. 4,	
				•		
Examiner		7				

Date Considered

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Substitute (use	for Fore	m 1449A/PTO (Modified) sheets as necessary P E	Attorney Docket No.: 04646.P003D	Application Number: 09/752,619
		FEB 2 0 2003 RS	First Named Inventor: Jesse Salb	
Page 1	of <u>1</u>	THE TANNEWS HE	Filing Date: 12/29/2000	
	·····	OTHER ART - NO PATEN	T LITERATURE DOCUMEN	TS
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL of the item (book, magazine, journal, se issue number(s), publishe	LETTERS), title of the article (who rial, symposium, catalog, etc.), date r, city and/or country where publi	e, page(s), volume-
M		BECH, LARS; DIEMER, NILS HENRII topical application of metrizamide to r pages 427-431 (June 1985).	K; and GJEDDE, ALBERT. "Me rat brain cortex." <u>Acta Neurol S</u>	etabolic effect of Scand., vol. 72,
pgl		GJEDDE, ALBERT. "The blood-brain Neurol. Scandinav. vol. 66, pages 392-3	barrier is impermeable to metri 395 (1982).	zamide." <u>Acta</u>
RA		SIGEL, PETER and PETTE, DIRK. "Inglycolytic enzymes in white and red racoupled enzyme reactions in histochem Cytochemistry, vol. 17, no. 4, pages 225	abbit skeletal muscle; a gel film nistry." The Journal of Histoch	method for
(-			
,				
· !				
		t .		

Date Considered

Examiner

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

^{&#}x27;Unique citation designation number. 'Applicant is to place a check mark here if English language Translation is attached.

_	
9 70 70	
s. 261	
-JE	
933	
Ď	

			_	_	_	0	_	<u>~</u>		D	4646,00031	, —	Sheet1	of	10_
orm PTO		9/	6) '	٠.	_				NT OF COMMERCE VADEMARK OFFICE	ATTY, DOCKET NO. 76958,P00	3.0	SERIAL NO. ()	9,734	2,49
			۲	AAI	R '	0	1	18.		ITATION	APPLICANT Jesse Salb				
INFOR	(MA	11/6) ; 7	AR.	ינ	ال. العم	SVETE C	v)	FILING DATE 9-8-98		GROUP /	6/ C	od
	103	0 30					_			TENT DOCL	JMENTS				
EXAMINER INITIAL		000	CUA	ÆN	TA	IUM:	BEI	R	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE PRIATE
AL		3	7	0	1	7	7	1	10/31/72	Almen et a	l.	260	211R	6/26	/70
N		3	8	5	4	0	4	9	12/10/74	Mistretta el	t al.	250	402	12/1	0/73
De		3	9	7	4	3	8	6	8/10/76	Mistretta et	t al.	250	402	3/27	
AR		4	2	4	3	6	5	3		Sovak et a		424	5	8/24	
AL	-	4	۲	5	t	†	t	+	┼──	Nordal et a		424	153	1	/80
AIL		4	3	6	14	19	1	2 1	12/21/82	Speck et a		1 424			
									FORE	GN PATENT	DOCUMENTS	- () =	NET		
		DOX	JJM	ENT	TN	UME	BEF	1	DATE	T	COUNTRY ()	CLASS		YES	NO
		T	T	T	T	T	T	T			673	1 0 4	עלנו	<u> </u>	
			T	I				I			GHr	10	000	 	
				I				1	<u> </u>	<u> </u>				1	<u> </u>
			(οт	Ή	EF	٦ ١	DO	CUMENTS	S (Including A	uthor, Title, Date, Pe	rtinent P	ages, Etc.)		
	Γ	Τ						5. e 97)		nacokinetics o	f aligonucleatides", (iba Four	ndation Symp	osium 2	09, pp
All			1				_	-	at at The	mechanism o	f regulation of hexok	nase: ne	w insights fro	orp the c	rystal
				str glu	uc	tur	e -€	of (S-pl	ecombinan osphate",	thuman brain Structure 6(1)	hexokinase complex :39-50 (1998).		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
D		\perp	\downarrow	• 11		_	_		-l *Eleve	dometric anal	ysis of glucose trans	port by r	at brain cells	. Cytor	netry
		L		27	:2	62	-2	68	(1997).						
10	1	\perp	_		_		_				for image registration				
11		-	4		_		- 11		Trainson (ar aralarantidi	phosphorylation of	ilucuse t	JY III (II CEITHICOC)	tumor conditali	y Y
1	+	+	4	ge	30	era	ıte	d A	TP", <i>J. Bio</i>	I. Chepr. 263(3	33):17422-17428 (No	v. 25, 19	98).		
11		-		В	an	net	н.	J.E.	G. of al., 'S	structural requ	irements for binding :211-221 (1973).	to the su	gar-transpor	t system	of the
124	+	+	_	Γ.	_	$\overline{}$					•				
N		1	_	В	an	nel	tt .	J.E vte	.G. et al., "E	vidence for tv	vo asymmetric confo Biochem. J. 145:41	mationa 7-429 (1	l states in the 975).	human	
EXAM	NER			1		<u>````</u>		, }	1.	Ī	DATE CONSIDER		د		
j/	11		~	1	Ü		\leq	0	drzue.	2	W 2.	2/670	MPEP 600-	Draw fin	
*EXAMI through applica	citat	; Ini ion ii	tial f no	ot i	cit n	cor	on	co	nsidered, w lance and n	nether or not on the considered.	citation is in conforma Include copy of this	form wit	h next comm	unicatio	n to

Mones

3/19/04

Ž)

09/752/619

	TO-14	Á9						CO DEPARTM				OHOU!	or
(REV. 8	3-83) /		44	• (١ 1	1		PATENT AND T	PADEMARK OFFICE	_76958.P0	03-	,	449.73
	/							<i>કું</i>		APPLICANT			
REV. 8-83 MAR 0 1 1839 APPLICATION A													
	/Us	Se se	AVA	_		_	to i	if nacassa.	n./ l				· · · · · ·
					3.,	-	-					— not ye	t assign
FORT PTO-1449 (REV. 8-83) MAR 0 1 1839 MAR													
'EXAMINER	1 1	00	CUM	ENT	NUM	(BE	1	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO
AL		4	4	5 5	2	9	2	6/19/84	Bertoni		424	5	4/5/
12		4	7	1 6	2	2	5	12/29/87	Ledley et al.		536	122	
AL		5	1]4	4 1	7	3	9	8/25/92	Jung et al.	· · · · · · · · · · · · · · · · · · ·	424	4	
AR		5	4 (8 0	9	9	6	4/25/95	Salb		128	633	
AL	\prod	5	4 6	6	7	8	6	11/14/95	Buhr et al.		536		
AL		5	6	0	2	8	9	3/11/97	Cook et al.	_			
			-									20.04	-4177
_								FOREIG	N PATENT DO	OCUMENTS			
		DOCU	MEN	TNU	MBE	A		DATE	co	JATTRY HT.	(ave	/stecks	
		Ш							-	LAN	3 0 9	1900	
		П	Т	Γ	П		T		1	P.10	*****	11222	
		П	T		П	1	Ť			Gir:	<u>C </u>	300	$\overline{}$
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) U.S. PATENT (Use several sheets if necessary) EVAMINER (Use several sheets if necessary) U.S. PATENT (Use several sheets if necessary) U.S. PAT													
			OTI	ΗE	Rι	OC	CL	INJENITO /					
		<u> </u>	Rine	100	~	~*	.	*Deserved	Including Autho	or, Title, Date, Pertir	ent Page	s, Etc.)	
.0		П	Bind	der	C.	et a	al.,	"Deregulate	ed simultaneou	s expression of mul	tiple aluce	se transpo	rter isofo
12			Bind in m	der nalie	C. gna	et a	al., cel	*Deregulate Is and tissu	ed simultaneou es*, <i>Anticancer</i>	s expression of mul Research, 17:4299	tiple glucc -4304 (19	ose transpor 997).	/
12			Bind in m	der nalig	C. gna	et a	al., cel	"Deregulate Is and tissu "Analysis of	ed simultaneou es*, <i>Anticancer</i>	s expression of mul Research, 17:4299	tiple glucc -4304 (19	ose transpor 997).	/
AZ An			Bind in m	der nalig	C. gna	et a	al., cel	"Deregulate Is and tissu "Analysis of	ed simultaneou es*, <i>Anticancer</i>	s expression of mul Research, 17:4299	tiple glucc -4304 (19	ose transpor 997).	/
12 11		E 1	Bird Bird 184:	R.	C. gna E. (3-6	et a	al., cei	*Deregulatels and tissue "Analysis of 1992).	ed simultaneou es", Anticancer cancers misse	s expression of mul Research, 17:4299 d at screening man synthetic 1251-lahe	tiple gluco -4304 (19	997). Radiolog	gy,
AL AM		E 1	Bird Bird 184:	R.	C. gna E. (3-6	et a	al., cei	*Deregulatels and tissue "Analysis of 1992).	ed simultaneou es", Anticancer cancers misse	s expression of mul Research, 17:4299 d at screening man synthetic 1251-lahe	tiple gluco -4304 (19	997). Radiolog	gy,
AZ AM AR		E 1	Bird 184: Chie	R.: 61:	C. na E. (.R	et ant ant ant ant ant ant ant ant ant an	al., cel	"Deregulatis and tissu "Analysis of 1992). "In vivo es m. J. Physic	ed simultaneou es", Anticancer cancers misse terification of a ol. 245:H693-H	s expression of mul Research, 17:4299 d at screening man synthetic 1251-labe 597 (1983).	tiple glucc +4304 (19 hmograph	ose transpoi 997). Y. Radiolog acid into car	gy,
AM AR		E 1	Bird Bird 184: Chie	R. 61:	C. ana	et ant at at 17	al., cel	"Deregulatis and tissu "Analysis of 192). "In vivo es m. J. Physic "Exploring".	ed simultaneou es", Anticancer cancers misse sterification of a ol. 245:H693-H	s expression of multi- Research, 17:4299 d at screening man synthetic 1251-labe 507 (1983).	tiple glucci +4304 (19 -4304 (19 	ose transpol 997). , Radiolog acid into car	gy,
AM AL	PTO-1449 8-83) MAR 0 1 1939												
AM AR	DOTE PTO-1449 NAR 0 1 1839 WAR 0 1 1839 NEV. 8-83) NEV. 8-83 NEV. 9-8-98 NEV. 9												
FORM PTO-1449 (REV. 8-83) MAR 0 1 1939 MAR						oy, n analys ver, brain 94:753-7							
AR AR	THE PTO-1449 WAR 0 1 1835 MAR 0 1 1835 MA												
FORM PTO-1449 (REV. 8-83) MAR 0 1 1939 MAR 1 1 1 1939 MAR 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1													
FORT PTO-1449 STREAM HONOLOGY STREAM HONOL													
AL AL AL XAMINE		E 1 1 C gg	Bird in m Bird 1184: Chie Chie Colvind 1199: Control	R. 61: 61: 61: 61: 61: 61: 61: 61: 61: 61:	C. ana S. A.	et ant ant ant ant ant ant ant ant ant an	al., (19 al., A spot al., 99	"Deregulatis and tissus and tissu	d simultaneouses", Anticancer cancers misse terification of a bl. 245:H693-H the hexokinas plucosamine interification of the structure ose transporter tisense Resear	s expression of multi- Research, 17:4295 d at screening man synthetic 1251-labe synthetic 1251-labe synthe	tiple glucc 4304 (18 nrnograph bled fatty a ite throug bib. 6:271- sugar bind date*, Nucleon	pse transpoi 1997). Y. Radiolog acid into car h correlation 282 (1993). lling to the lin ochem. J. 29 c. Med. & Bi	oy, ordiac. n analys ver, brain 24:753-7
AL AL AL XAMINE		E 1 1 C gg	Bird in m Bird 1184: Chie Chie Colvind 1199: Control	R. 61: 61: 61: 61: 61: 61: 61: 61: 61: 61:	C. ana S. A.	et ant ant ant ant ant ant ant ant ant an	al., cei	"Deregulatis and tissus and tissu	d simultaneouses", Anticancer cancers misse terification of a bl. 245:H693-H the hexokinas plucosamine interification of the structure ose transporter tisense Resear	s expression of multi- Research, 17:4295 d at screening man synthetic 1251-labe synthetic 1251-labe synthe	tiple glucc 4304 (18 nrnograph bled fatty a ite throug bib. 6:271- sugar bind date*, Nucleon	pse transpoi 1997). Y. Radiolog acid into car h correlation 282 (1993). lling to the lin ochem. J. 29 c. Med. & Bi	oy, ordiac. n analys ver, brain 24:753-7

Pones

3/19/04

3

			/	\leq	1	-	5	`		д	4646. Poc 3	\mathcal{G}	Sheet 3	of _	10
Form P1 (REV. 8-		149		•				Č		ENT OF COMMERCE RADEMARK OFFICE	ATTY, DOCKET NO.		SERIAL NO.		
(HEV. 6	63)	(M	AR	0	1	10	Ю			Z6958,P		- 09/	149,75	
INFO	RM	AFX								ITATION	Jesse Salb				
		/,	٦,					. (€ /		FILING DATE			-	•
 	(0	SØ SE	976	7.0	W &	BB	00	5 /	necessar	y)	9-8-98		Thot ye	t-assig	ned >
	T			_			_		U.S. PA	TENT DOCU	MENTS				
EXAMINER INITIAL		00	CUM	ŒN	TN	UMB	ER	_	DATE		NAME	CLASS	SUBCLASS	FILINI IF APPE	G DATE ROPRIATE
AL	<u> </u>	5	7	2	8	5	2	7	3/17/98	Singer et al		435	6	6/7	⁷ /95
AL		5	7	2	9	6	2	0	3/17/98	Wang		382	128	5/1	0/95
AL	_	5	7	6	3	2	익	8	6/9/98	Bischofberg	ger et al.	435	40.5	2/2	8/96
· -	FOREIGN PATENT DOCUMENTS: 0 2 1000 DOCUMENT HUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO														
	FOREIGN PATENT DOCUMENTS: DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO														
	FOREIGN PATENT DOCUMENTS: DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Dewanjee M.K. et al., "Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model", J. Nuc. Med.														
									FOREIG	N PATENT P	CUMENTS: 7	(L) (1) (1) (1)	. just T		
		DOCL	MEI	NT I	MUN	(BE)	•	7				1		TRANSI	ATION
	-			1	7	1	T	4			208-255-3 Fm 3-3	4		YEŞ	NO
		+H	Н	4	4	+	+	-				ļ	ļ		
		+	Ц	4	4	4	4	4				ļ	ļ		
								_]							<u>L.</u>
												-			
			ind	fiu	<u>m-</u>	11°	l-a	nt	isense prob	invasive imagi es in a mamm	ng of c- <i>myc</i> oncogo ary tumor-bearing	ne messe nouse mo	nger RNA w del", <i>J. Nuc</i> .	ith <i>Med</i> .	
AL			L.						, ,						
												ed PHIPA	3-10 in the r	at	
AR	Ì										·····				
1.1			Ek in i	ho rat	lm obi	S.	E.	et	al., "Neural a Radiologi	tissue uptake ca Diagnosis (and clearance of k Stockh), 26:331-33	hexol folio 6 (1985).	wing lumba	myelo	graphy
1														-	
4.			Elr	no	re vin:	J.C	a. c	et	al., "Ten-ye	ar risk of false	positive screening	mammogi	ams and clin	nical bro	ast
AR	Ì									7					
	T		Fri: 2:1	sto	on i	K.,	(1)	99	J., "Spatial	registration and	d normalization of i	mages*, H	uman Brain	Mappin	g
AL	- 1						`	_	_,		· ·· · · · · · · · · · · · · · · · · ·				
			Gh	05	e itis	A.H	ί. ε	et :	al., "Atomic	physicochemic	cal parameters for	three dime	nsional stru	cture di	rected
Alt	U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS U.S. PATEND DATE U.S. PATEND DATE														
EXAMIN	U.S. PATENT DOCUMENTS Suggisted to the process of the														
	_/	4ve	2 <u>Y</u>	2	_	4	d		Kodin	1162					
*EXAMINE through cit applicant.	R: Ir	nitial i if not	f cit	tat	ion	om	nar	id	ered, whethere and not co	er or not citationsidered. Incl	on is in conformand	e with MP	EP 609; Dra xt communic	w line cation to	,
		7	$\overline{\langle}$		_			_	20			10			
		1	4	_	1	10	Y	يا			3/19	64			
					1						/ /				

W

				1	P	E					04646. Pox	3D _	Sheet 4	of	10
Form P1		449	σ				35	EPARTI	MENT OF COM		ATTY, DOCKET NO.		SERIAL NO.		
(REV. 8-	-83)				u .	1 13	33	&)			-70958.P0	03	097	149,73	34
INFC	RM	AFE	m NO	νν D)IS	CLC	ാട	SI BRE (CITATIO)N	Jesse Salb				
		. \	É		7 m 41	new!			CITATIC		FILING DATE		GROUP	161	6
	()	se s	evē	rai	Ċ.	Bet\$	if n	ecessa	ary)		9-8-98		not ye	t assig	ned.
		,						U.S. P	ATENT	DOCL	JMENTS				
*EXAMINER		×	ЭСИМ	ENT	T NUM	IBER	\perp	DATE			NAME	CLASS	SUBCLASS	FILIN	G DATE
	_	_	\coprod	1	4	\coprod	\downarrow		ļ						
		<u> </u>	Ц	1	\downarrow	Ц	\perp						<u> </u>		
			Ц		\perp	Ш	L						·		
			Ц		\perp	Ц	L	·		j	RECEIVE				
	l		П	ı			1				1110 P. G. 600				
			П	7		П	T				Tradition of the think		1		
				_			_				Para Practice Property	71,	-		
								FORE	GN PATE	NT C	OCUMENTS				
	<u></u>	000	UMEN	NT N	UMBE	ER		DATE		c	OUNTRY	CLASS	SUBCLASS	YES	ATION
		Т	П	T	\prod	Π	Π								
			П	1	П		Τ								
		1	Ħ	1	Ħ	Π	T								
					ب		1								
· · · · · · · · · · · · · · · · · · ·											or, Title, Date, Perti				
			66:	39	2-39	95 (1	982	2).	am barner	is imp	ermeable to metriza	mide", Ad	aa Neuroi. S	candina	av.
AL	•														
	ı		Go sut	ima 200	an K xcipit	(.: °0 tal in)istri nject	ibution a ion in re	and retenti abbit, rat, a	ion of and ca	125I-labeled metriza it", Acta Radiol. Sup	mide afterpl. \$335:	r-intravenou 300-311 (19	is and 173).	
AR			Г												
			Hai	nsc las'	h C	et : Pha	al., '	Linear Sci. 61	relationshi (1):1-19 (J	ips be	tween lipophilic char	racter and	d biological a	activity	of
AM	Ì			J -	,,,,,				(1)1. 15 (<i>у.</i>	-			
711	_		Ha	nsc	'nС	. et a	al., '	"Explor	ing OSAR	: func	lamentals and applic	ations in	chemistry a	nd biolo	xgy".
M	ł		pp.	9/	-168	5, AI	ner.	Chem.	50C., Was	shingt	on, DC (1995).				
114	\dashv		Hei	nry	c	et al	. 41	231]-6-	deoxy-6-ic	do-D-	glucose (6DIG).: a p	otential t	racer of glue	cose	
10	ŀ		trar)sp	ort'	, Nu	C. M	led. Bio	/. 24:527- <u></u>	534 (1	997).	·	<u>-</u>		\dashv
11/4		4	Hol	h C	.K.	et al.	., *P	ET in o	ncoloav: w	rill it re	place the other mod	alities?"	Seminars in	Nuc M	ad
la	/		27(2):9	94-1	06 (Apri	i 1997)	6,					. 100. 10	
MICI			L.,												
EXAMINE	IΔ.		_		1.	7	7	1.		DAT	TE CONSIDERED				ł
	VTV	m	α	1//	4)	K	-0	drig	Um	1	X12210	đ			- 1
*FYAMINE	Q. 1-	nitial i	نا دنه	o tic	\n ~	Onsi	dera	M	hor e	-14 - 41	n is in conformance	*** ***			$\overline{}$

Te june)

3/19/04



			/	$\vec{}$	=		~				04646. Poz	3D	Sheet5	of	10
Form PTC (REV. 8-8		1		•	^			A	ENT OF COL	MMERCE COFFICE	ATTY, DOCKET NO. -76958.PG		SERIAL NO.	149,7	
INFOF			ŅΝ	DI	S	CLC		SPE C		NC	APPLICANT Jesse Salb				
	(Use	se	vel	TR.	\$D	MA OIS	if n	ecessa	ry) _		FILING DATE 9-8-98			Lassig	
								U.S. P.	ATENT	DOCL	JMENTS				
'EXAMINER INITIAL		DOX	CUME	ENT N	VUMI	BEA		DATE			NAME	CLASS	SUBCLASS	FILIN IF APPE	G DATE ROPRIATE
	_	_	4	1	L	\coprod	ig	···	-			ļ			
	\dashv	_	+	+	H	H	+		-			 			
	十		\dagger	\dagger	Н	H	\dagger					7 # pro,			
											14F (12	.009			
					Ш		L				J. 18 142 -	9 (3/			
							ı	OREIC	GN PATE	ENT C	OCUMENTS				
	D	ocu	MEN	TNU	MBE	:A		DATE		٥	OUNTRY	CLASS	SUBCLASS	TRANS	ATION
		Ц	1	\downarrow		\downarrow	_								
		Н	+	-	Н	\perp	igdash	<u></u>	-			ļ	<u> </u>		
		Ц		L	Ц		1		<u> </u>			ļ	Ļ		
- 1		Т	Hos	sok	awa	a R.,	, et a	il., "Myo	cardial k	inetics	of lodine-123-BMI	P in cani	ne myocardi	um afte	ır
AL			(19			sche	mia	and rep	erfusion:	implic	ations for clinical S	PECT*, <i>J</i> .	Nucl. Med. :	38:1857	-1863
								atty acid 1995).	flip-flop	in pho	spholipid bilayers is	extremel	y last, Bioc	hemistr	y
AL			Koo	20.		nt ol		40vomo	nt of fath	, add	, fatty acid analogu		in netan net		
10	-	+	pho	spł	oli	pid l	bilay	ers", Bi	ochemist	ry 32:1	1074-11086 (1993)	e acids acr		
AIL	+							pectral o		tions	or absorption-edge	fluorosco	py", <i>Medica</i>	l Physic	
AL															
									n-edge fl ay/June 1		opy using a three-s	pectrum t	echnique", /	Medical	
AL	+	4	Keli	er T	Г.Н	. et	aJ., :	Synthes	is and hy	/bridiza	ation properties of o	ligonucleo	ntides contai	nina	
AI	-	+	2'-0)-m	odi	fied	ribo	nucleoti	des", Nu	icleic A	Acids Res. 21(19):4	499-4505	(1993).		
EXAMINE	 R			,	_	_				DA	TE CONSIDERED	<u> </u>		<u> </u>	
14	\\\\	01	<u>~//</u>	6				ng			8/22	100			
EXAMINEF hrough cita ipplicant.	tion if i	aı if	in c	our ence	om	nand	ce si gete	a, wheti nd not c	ner or no considere	t citatio d. Inci	on is in conformance lude copy of this for	m with MPI	EP 609; Dra xt communic	w line cation to	,

Topones

2/19/04

Ó

				6	1 8	2	E)		04646. POC3	D	Sheet 6	of _	10
Form PT		49/	<i>F</i>	•			U.S. DEPARTME	ENT OF COMMERCE RADEMARK OFFICE	ATTY, DOCKET NO.		SERIAL NO.		
(REV. 8-	83)	- (ŀ	1AR	0	1 1	889 🏝		76958.PO)3 -	,_09/	149,73	4
		\:	•				24		APPLICANT				
INFO	HMA	4116	₹¥,	DIS	SCI	LO	SUBJE C	ITATION	Jesse Salb		T		
	(Us	se se	ever.	al s	PAD Hee	EM IS	if necessar	y)	9-8-98		GROUP ((હ Lassig	n d
							U.S. PA	TENT DOC	JMENTS				
*EXAMINER INITIAL		00	CUME	NT N	JMBE	R	DATE		NAME	CLASS	SUBCLASS	FILING	DATE
		_	П	П	Ť	Τ				 	 		
			H	$\dagger \dagger$	+								
			廾	H	\dagger						 		
			\vdash	H	Ť	\vdash				<u> </u>			
			H	H	\dagger	H				<u></u> _	-		
	┞┈┆		+	H	+	H							
			Щ	Ш		Ш			<u> </u>		I		\dashv
							FOREIG	N PATENT C	OCUMENTS				
		DOCL	MENT	NUM	8ER		DATE	٥	OUNTRY	CLASS	SUBCLASS	TRANSL	ATION
			$\overline{}$	П	_	Н						YES	МО
		Ш	\bot	Ц	\perp	Ц							
		Щ	\perp	Ц							1		
			L	Ш	\perp								
			OTI	4EF	R DO	oc	UMENTS	(Includina Auti	hor, Title, Date, Perti	nent Pec	es Etc.)		
									trast media in cell cu			o/. 15:68	-71
4.0	· }		(198	30).									
AL		_		_			****						
1			Aca	e S. d. S	ci. L	(a) /S/	., "Characte 4 86:3474-3	nzation of olig 478 (1989).	onucleotide transpor	t into livir	ig cells", Pi	oc. Nat	'
	ſ								agains and				
-1	\neg	\neg	Mac	hull	а Н.	J. 6	at al. *Comp	arative evalua	tion of fatty acids lab	eled with	C-11, Cl-34	m, Br-77	, and
	 						olic studies 178).	or the myocal	dium: concise comm	unication	, J. Nucl. I	vied.	\dashv
-+-	+	-	Mac	ovs	ki A.	et	al., "Isolate	d iodine image	es using spatial-frequ	iency end	coding", Ma	d. Phys	
	 	\dashv	6(1):	:53-	58 (Jar	VFeb 1979)					-	\dashv
	+	\dashv	Male	y F	. ej	a I.,	"Synthesis	of N-substitute	ed glucosamines and	their eff	ect on hexo	kinase".	
.	-	\dashv	J Bio	H, E	hen	1. 2	14:765-773	(1955).	-		-		
		4	Matt	euc	ci M	-	Oligonucleo	tide analogues	s: an overview", <i>Ciba</i>	Foundat	ion Sympos	ium 209	
1.1	** L	- 1	pp. 5										- 1
AL	Γ		Mey	lan ' licie	W.Ñ	l., . <i>J</i>	Atom/fragm	ent contributio i. 84(1):83-92	n method for estima (1995).	ting octar	nol-water pa	rtition	
EXAMINE	R				4	<u>~~</u>	<u> </u>		TE CONSIDERED		 		\dashv
	Hu	m	CI.	0	l_{v}	,	Kodn	ruz	8/22	100			
lhrough cit	R: Ini ation i	itial if f not	cita in or	tion onfo	con	sid	ered, wheth	er or not citationsidered. Inc	on is in conformance lude copy of this form	with MPE	EP 609; Drav	w line ation to	\neg
applicant.													- 1

Done?

2/19/04

Ď

				_	_	1	P	2		04646, Pob.	3D.	Sheet7	of _	10
		449	7	$\overline{}$	J			U.S. DEDA TIM	ENT OF COMMERCE TRADEMARK OFFICE	ATTY, DOCKET NO.		SERIAL NO.		
(MEV. 8-6	03)		1	ſ	M A I	• 1	1	14		76958.200	াত্ত	√09/	149,73	4
INFO	RM	ΔΤΙ	Źκ					<i>51</i>	ITATION	Jesse Salb				
""				\	~			AT /		FILING DATE		GROUP /	6/6	>
	(L	se s	eve	era	डि	100	M)	necessar	y)	9-8-98				
								U.S. PA	ATENT DOCU	JMENTS				
*EXAMINER INITIAL		~	CUL	MEN	TNU	мве	A	DATE		NAME	auss	SUBCLASS	FILING IF APPR	DATE OPRIATE
				Ц	Ц	1	L	<u> </u>						
		_	\downarrow	Н	1	╀	L							
		-	\perp	Н	4	+	┞			0.000	1513	e Park		
	Cocument Occument Neis J. N. Rainh hear Rekd Ried fluor Ries Can	H	+	╁	╁	<u> </u>		ig Hi	1 2 5]				
			Н	H	+	t	H		<u> </u>	of State Company	77	ļ <u>.</u>		
		<u></u>	L	آ	_1	Ĺ	Ĺ	Í	i	C.171 74 1	7 1	N/A		
·	PARTOCUMENTS INFORMATION DISCLOSURE CITATION (Use several should ricessary) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS COMMENT MARGER DATE COMMENT CASS SUBCLASS FRANCISCH VEST NO COMMENT MARGER DATE COMMENT COMMENT CASS SUBCLASS TRANSLATION FOREIGN PATENT DOCUMENTS COMMENT CO						FOREIG	N PATENT D	OCUMENTS					
		UME	NT P	- TANKE	ŒΑ		DATE	0	OUNTRY	CLASS	SUBCLASS			
		Т	Т	Г					 	YES	NO			
AL		?",												
1			۲					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, <u>(1000)</u> .					
-1			Ra	uito	on F	₹. e	t a	I., "Myocard	lial scintigraphy	with I-123 heptades	enoic ac	id as a test	or coro	nary
											einheim	nn 1-43/1	999)	
								, -woul	·/	77, 1011, 11	Janiotii,	pp. 1-40 (1)	, ,,,	
11			Ric	ede	rer	S	J. e	t al., Three	-bearn K-edge	imaging of iodine us	ing differe	nces betwe	en	455
			""	<u>910</u>	<u>, 347</u>	, pic	. VI	GOO HINESTES	AIGOTETICAL CO	insiderations, Med.	~nys. 8(4	ij:4/1~479 (JUVAUG	1981)
++			Ric	ede	erer	S.,	Le	il al., Three	-beam K-edge	imaging of iodine usi	ing differe	ences betwe	en	
			<u>su</u>	<u>oro</u>	SO	pic	Vi	deo images	: experimental	results", Med. Phys.	8(4):480	-487 (JuVA:	ig 1981)
10	\exists	_	Rid Çê	es l	LA er .	.G. Stat	et ist	al. (eds).: "S ics Review,	Surveillance, E _l 1973-1995, Na	pidemiology, and Endational Cancer Institu	d Results te, 42 pa	Program, 1 s. (1998).	998," <i>Si</i>	EER
1714	AINER AINER: Initial if the citation if not												95 (195	54).
EXAMINE		_		_	_		1 -							
Vtr	<u>~l</u>	77	ŹΨ	2	1	K	0	unqua	2	8/22/8	20			
*EXAMINEI through cita applicant.	DOOGUN DO	if ci t in	tati	on nfo	con	sic	lered, whethe and not co	ner or not citation onsidered. Incl	on is in conformance lude copy of this form	with MPE	EP 609; Dra kt communic	w line ation to		
				_		_	_							

reforms Appel

Ø

	/ () ·	PE		04640.Poz	うi)s	Sheet 8	of	10
Form PTO-1 (REV. 8-83)	1	U.S. DEPARTAL PATENT AND T	NT OF COMMERCE RADEMARK OFFICE	ATTY, DOCKET NO. 76958.P00	99	SERIAL NO. -09/	149,73	4
INFORM	MATION TASCLO	OSURE O		APPLICANT Jesse Salb	_T		, , , , ,	<i>(</i>
	Use several sheets	DEM		FILING DATE 9-8-98	ĺ	GROUP / I	ر / نها Lassig	ned.
		U.S. PA	ATENT DOCU	MENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING	DATE OPRIATE
		 						
		-	<u> </u>	5-4 July 17 7	1	¹.		
	 			1				
	<u> </u>	<u> </u>						
		FOREIG	IN PATENT D			:		
	DOCUMENT NUMBER	DATE	œ	VUNTRY	CLASS	SUBCLASS	TRANSL	ATION
		1					163	NO.
		1						
	OTHER DO	CLIMENTS	(Including Auth	or, Title, Date, Perti		. 51.	<u></u>	
T	Speck U., "Ba	sic pharmac		ed contrast media",			1-13. CI	nurchi
AC	Livingstone, N	IY (1988).					·	_
	1 1					,		_
1				human beta-cell glud		uilt by anal	00y 10 t	he
				human beta-cell glud Diabetes 43:784-79		uilt by anal	ogy 10 t	he
	Tavitian B. et	al., "In vivo in	nexokinase B*,		<u>1 (1994).</u>			
	crystal structu	al., "In vivo in	nexokinase B*,	Diabetes 43:784-79	<u>1 (1994).</u>			
	Tavitian B. et Nature Medici	al., "In vivo ir ine 4(4):467-4	maging of oligo 471 (1998).	Diabetes 43:784-79 nucleotides with pos	1 (1994).	sion tomog	graphy",	
	Tavitian B. et Nature Medici	al., "In vivo ir ine 4(4):467-4	mexokinase B*, maging of oligo 471 (1998).	Diabetes 43:784-79 nucleotides with pos	1 (1994).	sion tomog	graphy",	
	Tavitian B. et Nature Medica Torikuza K. et (123I-BMIPP) Trigatti B.L. et	al., "In vivo ir ine 4(4):487-4 t al., "A Phas", Jpn. J. Nuc	maging of oligo 471 (1998). se 1 study of be cl. Med. 28:681	Diabetes 43:784-79 nucleotides with pos na-methyl-p-(1231)-ic -690 (1991).	odophenyl	-pentadeca	raphy",	id
	Tavitian B. et Nature Medica Torikuza K. et (1231-BMIPP) Trigatti B.L. et adipocytes: et	al., "In vivo ir ine 4(4):467 de tal., "A Phase", Jpn. J. Nuc	maging of oligo 471 (1998). e 1 study of be cl. Med. 28:681 ect of intracellu uptake involve	Diabetes 43:784-79 nucleotides with pos na-methyl-p-(1231)-ic -690 (1991).	itron emis	-pentadeca	raphy",	id
	Tavitian B. et Nature Medica Torikuza K. et (1231-BMIPP) Trigatti B.L. et adipocytes: et acids across t	al., "In vivo ir ine 4(4):467-4 t al., "A Phase", Jpn. J. Nuclei t al., "The effect of the plasma met al., "The c	maging of oligo 471 (1998). se 1 study of be cl. Med. 28:681 ect of intracellu uptake involve tembrane", Bioc	Diabetes 43:784-79 mucleotides with pos ma-methyl-p-(1231)-id -690 (1991). lar pH on long-chains the passive diffusion. Chem. J. 313:487-49 collity of breast cance	odophenyl fatty acid on of prot (1996).	-pentadeca uptake in 3 onated lon	raphy*, noic ac 3T3-L1 g-chain	id
AR	Tavitian B. et Nature Medica Torikuza K. et (1231-BMIPP) Trigatti B.L. et adipocytes: et acids across to yan Dijck J.A. program. A re	al., "In vivo ir ine 4(4):467— t al., "A Phase", Jpn. J. Nucleonice that the plasma met al., "The cycleonice of the plasma met al.," The cycleonice of the plasma met al., "The cycleonice of the plasma met al.," The cycleonice of the plasma met al.," The cycleonical methods are all methods and all methods are all methods	maging of oligo 471 (1998). se 1 study of be cl. Med. 28:681 ect of intracellu uptake involve tembrane", Bioc	Diabetes 43:784-79 mucleotides with pos ma-methyl-p-(1231)-id -690 (1991). lar pH on long-chain s the passive diffusi chem. J. 313:487-49 polity of breast cance ograms of interval at	odophenyl fatty acid on of prot (1996).	-pentadeca uptake in 3 onated lon	raphy*, noic ac 3T3-L1 g-chain	id
AR	Tavitian B. et Nature Medica Torikuza K. et (1231-BMIPP) Trigatti B.L. et adipocytes: et acids across to yan Dijck J.A. program. A re	al., "In vivo ir ine 4(4):467— t al., "A Phase", Jpn. J. Nucleonice that the plasma met al., "The cycleonice of the plasma met al.," The cycleonice of the plasma met al., "The cycleonice of the plasma met al.," The cycleonice of the plasma met al.," The cycleonical methods are all methods and all methods are all methods	maging of oligo 471 (1998). se 1 study of be cl. Med. 28:681 ect of intracellu uptake involve tembrane", Biox current detectal revious mamm Sept 15, 1993).	Diabetes 43:784-79 mucleotides with pos ma-methyl-p-(1231)-id -690 (1991). lar pH on long-chain s the passive diffusi chem. J. 313:487-49 polity of breast cance ograms of interval at	odophenyl fatty acid on of prot (1996).	-pentadeca uptake in 3 onated lon	raphy*, noic ac 3T3-L1 g-chain	id
	Tavitian B. et Nature Medica Torikuza K. et (1231-BMIPP) Trigatti B.L. et adipocytes: et acids across to yan Dijck J.A. program. A re	al., "In vivo ir ine 4(4):467— It al., "A Phase", Jpn. J. Nucleonice that the plasma met al., "The ciview of the pisson of the p	maging of oligo 471 (1998). e 1 study of be cl. Med. 28:681 ect of intracellu uptake involve tembrane", Bioc current detectat revious mamm Sept 15, 1993). DAT	Diabetes 43:784-79 nucleotides with pos na-methyl-p-(1231)-ic -690 (1991). lar pH on long-chain s the passive diffusi chem. J. 313:487-49 polity of breast cance ograms of interval an	iteron emis odophenyl (fatty acid ion of prot (4 (1996). (r in a man nd screen-	-pentadeca uptake in 3 onated ion nmographic	graphy", unoic ac 3T3-L1 g-chain c screen ancers",	id

+ Apres

3/19/21

Æ)

			_	<u>61</u>	2		04646, 170C	31)	Sheet9	of _	10	
Form PTC			,	-	U.S. DEPART	ENT OF COMMERCE RADEMARK OFFICE	ATTY, DOCKET NO.		SERIAL NO.			
(REV. 8-8	3)	-{	A	AR G	1 1939 🏝		76958.00	93-	100/	149,73	4	
INFO	38 4 A T		•		L.1	ITATION	Jesse Salb					
INFOR	NVIA I	IUN	(K)	SULU 2 m	SURE	HAHON	FILING DATE		GROUP	1.16	>	
	(Use	seve	ral :	Sheets	ff necessar	y)	9-8-98			t assign	red	
	·				U.S. PA	ATENT DOCU	JMENTS					
'EXAMINER		осим	ENT P	YUMBER	DATE		NAME	CLASS	SUBCLASS	FILING	DATE	
	\dashv	TT	7	П						IF APPR	PRIATE	
	_	+	+	H	 			<u> </u>				
		Щ	\perp	Ш								
						1						
		П					•••					
		П	T	\prod					,a			
	一	11	Ť	H					1			
COUNTRY CONSTRUCTION OF THE COUNTRY CONTRY	<u> </u>											
					FOREIG	N PATENT C	OCUMENTS					
Τ	00	CUMEN	UN TV	MBER	DATE	C	OUNTRY	CLASS	SUBCLASS	TRANSLATION		
		11	T			,			ļ	YES	Ю	
		44	\perp									
								i				
	Ì	П	T									
										<u></u>		
							nor, Title, Date, Pert				_	
Ì	<u> </u>						ur. Heart J. 11:258-2			actorin		
12												
i					al., "A reviev 15 (1991).	w of false nega	tive mammography	in a symp	tomatic pop	ulation",	Clin.	
j	<u> </u>	/ ""	aioi.	77. 13-	13 (1991).							
		We	ber	G., "M	elecular corre	elation concept	t: ordered pattern of	gene exc	ression in n	eoplasia	-	
	1_	GA	WN	Monog	raph on Can	cer Res 13:47	77 (1972).			.,		
11											j	
		her	sinho pato	ouse S. mas", <i>(</i>	, "Glycolysis Ancer Res.	, respiration, a 32(10):2007-20	nd anomalous gene 016 (1972).	expression	on in experir	nental		
		Г	/							acid In ulation", Clin. eoplasia", nental		
+		Wil	Ison	M. et a	J. Yeast he	xokinase inhib	itors designed from	the 3-D e	nzyme struc	ture		
	1	reb	uildi	ing", J.	Enz. Inhib. 1	12:101-121 (19	97).					
11		W/a		D P 6	ol "Auto-	nated image	gistration: I. Genera			bi		
AL	_	intr	amo	dality v	alidation", J	. Comput. Assi	ist. Tomogr. 22(1):13	39-152 (1	998).	ibject,		
						· · · · · · · · · · · · · · · · · · ·						
EXAMINE	ን		1			DAT	TE CONSIDERED					
<i></i>	tim	an	<u>00</u>	<u> K</u>	00/1911	0	8/22/06)				
*EXAMINER	tion if a	if cit	atio	n consi	dered, wheth	ner or not citatio	on is in conformance lude copy of this for	with MPI	EP 609; Dra	w line		
applicant.				- The state of the	o and HUCC	ZI ISIUEI BU. IIICI		n wiin ne:	kt communic	ation to	1	

V Jues

3/19/04

Ø

				_	_	_	<u> </u>	_			à	1646	,P003	D	Sheet10	of _	10
Form PT (REV. 8-		449	7	7	7	•		S. D.	MIRAPS ON CO	ENT OF COM		ATTY. DO	OCKET NO.		SERIAL NO.		
(NEV. 6-	03)	- [ट्र।			APPLICA	76958.P0	103	-09/	149,7	34
INFO	RM.	AΤ	3 N	ישי היי	AK SIC	TU SC	1 :1 C	1359 OSU	Ref C	TATIC	N		e Salb				
	,	, , ,	1	1,		-		79	了	OTATIC	/1 \	FILING D	ATE		GROUP	16/	6
	(U	se s	evè	76	(§	M	H.P	Life	cessa	ry)			9-8-98		not-ye	t assig	ned
								ι	J.S. P	ATENT C	ocu	MENT	S				
'EXAMINER LAITINI		ox	CUL	KEN	T NO.	ЈМВ	EΑ		DATE			NAME		class	SUBCLASS	FILIN IF APPI	G DATE ROPRIATE
				Ц		\downarrow	1	<u> </u>						<u> </u>			
		L	\sqcup	Ц		4	_	ļ						ļ 	ļ		
	ļ		Ц	Ц		1	1	<u> </u>		ļ			- :		*		
	_	L	Ц	Ц	Ц	4	\downarrow	_	<u>.</u>	 				<u> </u>			
		Ŀ	Ц	Ц	4	4	4	ــــ		<u> </u>		•			<u> </u>		·
			Ш	Ц		1	1	<u> </u>		<u> </u> 		٠.	I Wasa	1 10	<u>h</u>		
								_	2551								
								ī		3N PATE			ENIS	<u></u>		TRANS	ATION
	DOCUMENT NUMBER			L °	ATE	TE COUNTRY CL			CLASS	SUBCLASS	YES	NO					
					T												
			П		T		T										
			0	TH	EF	3 0	000	CUMI	ENTS	(Includin	a Auth	or Title	Date Per	Finant Page	e Ftc)		
· ·			W	001	ds	Ř.I	5. e	t al '	Auton	nated ima	Ge ree	Istration	: II. Intersu	biect valid		ar and	
41			no	MILI	nea	ar r	noc	leis",	J. Con	nput Assi	st. I o	mogr. 22	2(1):153-16	5 (1998).			
nu			w	09	ie-	FI.F	5 e	t al., *	MRI-P	ET regist	ration	with aut	omated alg	orithm", J.	Comput. A	ssist. To	omogr.
n		_	17	(4)	:53	36-	<u>546</u>	(July	/Aug1	993).				-			
AL	\leq		L			_											
	ı				,			,					_		YES NO Iges, Etc.) idation of linear and		
		_															ING DATE PROPRIATE
			Г		_	_		•									
-																	
			\vdash			_		-						_=			
				_	_							<u>.</u>					
	ŀ		H		_												
EXAMINE			L	-		_					DAT	E CON	ISIDERED)	_	-	
					_	_											
*EXAMINE through cit applicant.	:R: Ir ation	nitial if no	if ci	co	ion nfo	co	nsid	dered	, whell d not o	her or not onsidered	citatio	n is in c ude cop	onformanc y of this for	e with MPE	P 609; Dra d communi	w line cation to	0

1 Spring

3/19/01

 \mathscr{D}

04646.P003D Sheet Form PTO-1449 ATTY, DOCKET NO. SERIAL NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 8-83) 76958-P903 __09/149,734 APPLICANT Jesse Salb INFORMATION DISCLOSURE CITATION 1616 FILING DATE GROUP (Use several sheets if necessary) 9-8-98 not yet assigned U.S. PATENT DOCUMENTS EXAMINER INITIAL FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS 3/30/1993 Salb 364 413.01 11/27/1990 FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER COUNTRY OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER** DATE CONSIDERED *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Dos

3/19/04

(Z)

					(646.7003	0			PE	100 3 3 C
F rm PTO-1449 (Modified)				Aus D cl	(t No.:	Seri	al N .:	7)	ان مس
				076958 P	100	-00/1	40. 304-		Mrs. I.	3
List of	Pater	nts and	Publications	Statement	903	Applicant:	49,734 -		WATE TO	NDE TREE
			s if necessa			Jesse Salb			- CE.	
						Filing Dat:	September 8,	1998		
REFEF	RENC	E DES	IGNATION		U.S. P	ATENT DOCU	MENTS			
Examir	ner		Docum	nent No.			Class	Su	b- Fi	ling date
Initials					<u> </u>			Cla		appropriate
	42		A 5,093,	042	Counsell	et al.	260	408	3 4/	20/90
			AB .							
			<u>.c</u>							
			<u>.D</u>		-					
			E		-					
			G G							
		- 1	н							
		\rightarrow	M							
		Α	J					1.		
F		A	ĸ							
No.		Do	cument No.	Date		TENT DOCUME	ENTS Clas	ass Sub-		Trans-
	AL			•		· 1	· · · · · · · · · · · · · · · · · · ·		01033	Idion
	AN		_							
	A١									
	AC		· · · · · · · · · · · · · · · · · · ·							
	AF									
•			OTHER	R ART (Inclu	iding Author	r, Title, Date, F	Pertinent Pages	s, etc.)		
N		AR	Neurol. Sca	and. Vol. 72	рр. 427-431	(1985).	n of metrizamide			· - · · · · · · · · · · · · · · · · · ·
AL	,					•	ellular localizatio			•
	_	AS					. 15 pp. S215-S			
AV	,]	AT					mulation of radio			media in
xamin	-		me rat kidh	ey (and disc		inning Microsc. onsidered	4:3 pp. 651-66	0 (1990))·	
	ı/l	mano	6 Zm	riguez	Date G		127/00			
						<u></u>	7 -1 00			
EXAMIN		Initial i	f reference o	considered v	whether or no	ot citation is in	conformance wit	th MPFF	609 Dr	aw line

09/753,609 04646, PO831) Atty Docket No.: Form PTO-1449 (Modified) Serial N .: 09/149,734 List of Patents and Publications Statement Applicant: (Use several sheets if necessary) Jesse Salb. Filing Date: September 8, 1998 REFERENCE DESIGNATION **U.S. PATENT DOCUMENTS** Examiner Document No. Class Sub-Filing date Initials Class if appropriate AA AB AC AD ΑE AF AG AH Αl ΑJ AK **FOREIGN PATENT DOCUMENTS** No. Document No. Date Country Class Sub-Trans-Class lation AL AM AN AO OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.) Nordby A. et al., "Incorporation of contrast media in cultured cells," Invest. Badiol. Vol. 24 ΑP pp.703-710 (Sept. 1989). Nordby A. et al., "Effects on the ATP content of cultured cells after radiographic contrast media AQ exposure. Evidence for accumulation of contrast media in cultured cells," Acta Radiol. Vol. 30 pp. 541-547 (1989). Nordby A. et al., "Short-term effects of radiographic contrast media on monolayer cell cultures and hepatocytes," Invest. Radiol. Vol. 22 pp. 603-607 (July 1987). Examiner **Date Considered** EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10 mes

3/19/04

Ø)

	_				D41	-46, Por	30		D	9/75	а, 	Le(9		
Form F	РТО	-144	9 (Mc	dified)	Atty D cket	N .:		Serial No.:		MAR 2	an T			
					0 76958.P003	A)		0 9/149,734						
1				ublications			Applic			ATENTS!	RADEN			
(Use se	ever	al sh	ieets i	f necessary	')		Jesse Filing		mber 8, 19					

REFER	REN	CE [DESIG	NATION		U.S. P	ATENT	DOCUMENTS						
				Docume	ent No.				Class	Sub-	Filin	g date		
Initials										Class	if appropriate			
			AA AB								 			
			AC											
			AD											
•			AE AF							 	-			
			AG								 			
			AH											
			Al	-						<u> </u>	-			
***			AJ AK							1	<u> </u>			
		1	711					<u> </u>	1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	J	<u> </u>			
					FOR	EIGN PAT	ENT DO	CUMENTS						
No.			Docu	ment No.	Date	Coi	untry		Class	Sub- Class	3	Trans- lation		
	A													
	<u>A</u>													
_	A	- 1						<u> </u>		_				
	Α	Р												
				OTHER	ART (includir	ng Author	, Title, I	Date, Pertinen	t Pages, e	tc.)				
Au		AI				f radiographic contrast media on monolayer cell cultures," Invest.								
•	. 7			-	ol. 21 pp. 234-239 (March 1986). J.P. et al., "Polyiodinated triglyceride analogs as potential computed tomography									
AN	_	AS	S ir	naging age	nts for the live	r," J. Med.	Chem.	Vol. 38 No. 4 p	p. 636-646	(1995).				
		A	r											
Examine	er	A	ame	ndo	2 odvicuse	Date Co	nsidere	8/27/0	·)					
	cita							n is in conform copy of this fo						

Mones

3/19/04

15

List of I (Use se	Patents everal si	and Pub neets if n	olications St	atement	. ~	\	'	: Jesse Sa			
				M 2	2000	5	Filing Dat	te: Septem	ber 8, 199	8	
REFE	RENCE	DESI	GNATION	\@ _\	HWERE	/	DOCUMEN	ITS			
Examin Initials	er		Document					Class	Sub- Class	Filing if ap	date propriate
7	<i>K</i>	ÃA	4,887,604	1	Shefe	r et al.		128	654	05-1	6-1988
		AB								_	
		AC	ļ		 			 			
		AD AE									
		AF									
		AG			-			 	-	-	
	-	AH	 		 			+	+		
		AJ									
		AK								-	
		AL AM			-						
		AN	<u></u>								
		AO								1	
		AP	<u>L </u>		<u> </u>		<u>-</u>	<u> </u>	<u> </u>	1	
				FORE	EIGN	PATENT I	OCUMENT	rs			
No.		Docum	nent No.	Date		Country		Class	Sub-	Class	Trans- lation
N	AQ		270 340	06-08-		Europe					
AR	AR	WO 9	8/57669	12-23-	1998	WIPO		· ·			
	AS	 		1							
	ÂU										
				•			Date, Per			_	
M	AV	PCT Ir (7 pag	nternational es).	Search R	eport fo	or PCT Int'l A	ppin No. PC	T/US99/202			5, 2000
	AW									10)	丁
									,	3636	四四
	AX	-				- 19				 	
	AY	-	<u> </u>	-		· · · · · · · · · · · · · · · · · · ·				<u>;>-</u> ;	
	AZ				Thete	Considered				E0011	
	ner 1		PI	GUEZ	Date	Considered	8/	22/00		2	
Examir	Hr	rante	NOUT	9000	1		on is in confo				

Hous

3/19/04

B